Distinguishing Persistent Insulin Autoantibodies With Differential Risk
Open Access
- 12 December 2011
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 61 (1) , 179-186
Abstract
A subset of children develops persistent insulin autoantibodies (IAA; almost always as the only islet autoantibody) without evidence of progression to diabetes. The aim of the current study was the development and characterization of the performance of a nonradioactive fluid phase IAA assay in relation to standard IAA radioassay. We developed a nonradioactive IAA assay where bivalent IAA cross-link two insulin moieties in a fluid phase. The serum samples positive for anti-islet autoantibodies from 150 newly diagnosed patients with diabetes (Barbara Davis Center plus Diabetes Autoantibody Standardization Program [DASP] workshop) and 70 prediabetic subjects who were followed to diabetes were studied. In addition, sequential samples from 64 nondiabetic subjects who were persistently IAA+ were analyzed. With 99th percentile of specificity, the new assay with the technology from Meso Scale Discovery Company (MSD-IAA) detects as positive 61% (61 of 100) of new-onset patients and 80% (56 of 70) of prediabetic patients compared with our current fluid phase micro-IAA radioassay (mIAA; 44 and 74%, respectively). In addition, MSD-IAA demonstrated better sensitivity than our mIAA from blinded DASP workshop (68 vs. 56% with the same 99% specificity). Of 64 IAA+ nondiabetic subjects, 25% (8 of 32) who had only IAA and thus the low risk for progression to diabetes were positive with MSD-IAA assay. In contrast, 100% (32 of 32) high-risk children (IAA plus other islet autoantibodies) were positive with MSD-IAA. The IAA detectable by radioassay, but not MSD-IAA, were usually of lower affinity compared with the IAA of the high-risk children. These data suggest that a subset of IAA with current radioassay (not MSD-IAA) represents biologic false positives in terms of autoimmunity leading to diabetes. We hypothesize that factors related to the mechanism of loss of tolerance leading to diabetes determine high affinity and MSD-IAA reactivity.Keywords
This publication has 24 references indexed in Scilit:
- Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2009
- Murine High Specificity/Sensitivity Competitive Europium Insulin Autoantibody AssayDiabetes Technology & Therapeutics, 2009
- SlC30A8 Is a Major Target of Humoral Autoimmunity in Type 1 Diabetes and a Predictive Marker in PrediabetesAnnals of the New York Academy of Sciences, 2008
- Accepting clocks that tell time poorly: Fluid-phase versus standard ELISA autoantibody assaysClinical Immunology, 2007
- Identification of insulin autoantibodies of IgA isotype that preferentially target non-human insulinClinical Immunology, 2007
- Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization ProgramClinical Immunology, 2007
- The Second Murine Autoantibody WorkshopAnnals of the New York Academy of Sciences, 2003
- A Novel Micro-assay for Insulin AutoantibodiesJournal of Autoimmunity, 1997
- Insulin Antibodies in Insulin-Dependent Diabetics Before Insulin TreatmentScience, 1983
- METHIMAZOLE AND INSULIN AUTOIMMUNE SYNDROME WITH HYPOGLYCAEMIAThe Lancet, 1983